Gladstone Capital (NASDAQ:GLAD) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.23 by 8.7 percent. This is unchanged from the same period last year.
Akari Therapeutics Announces Existing Investors Support The Company Through A $2M Private Placement Financing, Company Also Receives $2.5M U.K. R&D Tax Credit
Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has entered into
